Answers are grounded in this paper and cite their sources.
Case report reveals benign complex sclerosing lesion mimicking neuroendocrine tumor on imaging, suggesting diagnostic challenges.
[68Ga]Ga-DOTATATE PET/CT assists in the identification of neuroendocrine tumors (NETs). The administered radiopharmaceutical, [68Ga]Ga-DOTATATE, binds to somatostatin receptors (SSTRs). Overexpression of SSTRs in NETs allows increased somatostatin analogue (SSA) avidity on PET/CT. Although [68Ga]Ga-DOTATATE PET/CT has high specificity for detecting NETs, there are known causes of false-positives, including breast carcinomas and fibroadenomas. We present a case of a young woman with recently diagnosed medullary thyroid cancer for whom staging [68Ga]Ga-DOTATATE PET/CT incidentally revealed an avid lesion in the right breast, which was subsequently shown to be a benign complex sclerosing lesion (CSL). To our knowledge, there are no documented cases of CSLs showing SSA avidity on [68Ga]Ga-DOTATATE PET/CT. This case suggests that CSLs have potential for [68Ga]Ga-DOTATATE binding and should be considered in the differential diagnosis for SSA-avid breast lesions. Ultimately, additional investigation is needed to elucidate the mechanism of SSA avidity in CSLs.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: